Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Drug Resistance Updates

Volumn 15, Issue 1-2, 2012, Pages 50-61

  Amiri Kordestani, Laleh ^a   Basseville, Agnes ^a   Kurdziel, Karen ^a   Fojo, Antonio Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

18F fluoropaclitaxel; Breast cancer; Drug penetration; Lung cancer; MDR 1 Pgp

Indexed keywords

AMIODARONE; ANTHRACYCLINE; AXITINIB; BEPRIDIL; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DEXVERAPAMIL; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; LAPATINIB; LONIDAMINE; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; QUINIDINE; SORAFENIB; SULINDAC; SUNITINIB; TAMOXIFEN; TARIQUIDAR; TOPOTECAN; TRIFLUOPERAZINE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG ACCUMULATION; DRUG TARGETING; DRUG UPTAKE; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; ONCOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84860669151     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.02.002     Document Type: Article

References (148)

1. N.J. Abbott, L. Ronnback, and E. Hansson Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 7 2006 41 53
2. J. Abraham, M. Edgerly, R. Wilson, C. Chen, A. Rutt, and S. Bakke A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine Clin. Cancer Res. 15 2009 3574 3582
3. M. Agrawal, J. Abraham, F.M. Balis, M. Edgerly, W.D. Stein, and S. Bates Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576 Clin. Cancer Res. 9 2003 650 656
4. Allebrandt, K.V., Amin, N., Muller-Myhsok, B., Esko, T., Teder-Laving, M., Azevedo, R.V. et al., 2011. A K(ATP) channel gene effect on sleep duration: from genome-wide association studies to function in Drosophila. Mol. Psychiatry, in press.
5. O. Alonso, L. Delgado, M. Nunez, C. Vargas, J. Lopera, and P. Andruskevicius Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer Nucl. Med. Commun. 23 2002 765 771
6. P. Arcan, E. Ibis, G. Aras, R. Cam, and N.O. Kucuk Identification of sentinel lymph node in stage I-II breast cancer with lymphoscintigraphy and surgical gamma probe: comparison of Tc-99m MIBI and Tc-99m sulfur colloid Clin. Nucl. Med. 30 2005 317 321
7. C. Atalay, I. Deliloglu Gurhan, C. Irkkan, and U. Gunduz Multidrug resistance in locally advanced breast cancer Tumour Biol. 27 2006 309 318
8. C. Atalay, A. Demirkazik, and U. Gunduz Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer J. Chemother. 20 2008 734 739
9. E.K. Baker, R.W. Johnstone, J.R. Zalcberg, and A. El-Osta Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs Oncogene 24 2005 8061 8075
10. S.E. Bates, S. Bakke, M. Kang, R.W. Robey, S. Zhai, and P. Thambi A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma Clin. Cancer Res. 10 2004 4724 4733
11. S.E. Bates, B. Meadows, B.R. Goldspiel, A. Denicoff, T.B. Le, and E. Tucker A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer Cancer Chemother. Pharmacol. 35 1995 457 463
12. S.E. Bates, Z. Zhan, K. Steadman, T. Obrzut, V. Luchenko, and R. Frye Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma Br. J. Haematol. 148 2010 256 267
13. D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini, M.J. Goudier, and I. Krakowski Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma Ann. Oncol. 11 2000 1471 1476
14. S.L. Berg, A. Tolcher, J.A. O'Shaughnessy, A.M. Denicoff, M. Noone, and F.P. Ognibene Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer J. Clin. Oncol. 13 1995 2039 2042
15. A. Brozik, C. Hegedus, Z. Erdei, T. Hegedus, C. Ozvegy-Laczka, and G. Szakacs Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin. Drug Metab. Toxicol. 7 2011 623 642
16. A.M. Brufsky, M. Mayer, H.S. Rugo, P.A. Kaufman, E. Tan-Chiu, and D. Tripathy Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin. Cancer Res. 17 2011 4834 4843
17. G.T. Budd, R.M. Bukowski, A. Lichtin, L. Bauer, P. Van Kirk, and R. Ganapathi Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer Invest. New Drugs 11 1993 75 79
18. H. Burger, J.A. Foekens, M.P. Look, M.E. Meijer-van Gelder, J.G. Klijn, and E.A. Wiemer RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response Clin. Cancer Res. 9 2003 827 836
19. R.W. Carlson, A.M. O'Neill, L.J. Goldstein, B.I. Sikic, N. Abramson, and J.A. Stewart A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group Cancer Invest. 24 2006 677 681
20. I. Cascorbi Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs Pharmacol. Ther. 112 2006 457 473
21. L. Ceriani, L. Giovanella, M. Bandera, B. Beghe, M. Ortelli, and G. Roncari Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy Nucl. Med. Commun. 18 1997 1087 1097
22. Y. Chen, Y. Tang, S. Chen, and D. Nie Regulation of drug resistance by human pregnane X receptor in breast cancer Cancer Biol. Ther. 8 2009 1265 1272
23. Y. Chen, Y. Tang, M.T. Wang, S. Zeng, and D. Nie Human pregnane X receptor and resistance to chemotherapy in prostate cancer Cancer Res. 67 2007 10361 10367
24. Y.J. Chen, W.C. Huang, Y.L. Wei, S.C. Hsu, P. Yuan, and H.Y. Lin Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells PLoS ONE 6 2011 e21428
25. Chintamani, J.P. Singh, M.K. Mittal, S. Saxena, A. Bansal, and A. Bhatia Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer - a prospective clinical study World J. Surg. Oncol. 3 2005 61
26. A. Ciarmiello, S. Del Vecchio, P. Silvestro, M.I. Potena, M.V. Carriero, and R. Thomas Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer J. Clin. Oncol. 16 1998 1677 1683
27. R. Clarke, F. Leonessa, and B. Trock Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis Semin. Oncol. 32 2005 S9 S15
28. M. Colone, A. Calcabrini, L. Toccacieli, G. Bozzuto, A. Stringaro, and M. Gentile The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J. Invest. Dermatol. 128 2008 957 971
29. L.R. Coover, G. Caravaglia, and P. Kuhn Scintimammography with dedicated breast camera detects and localizes occult carcinoma J. Nucl. Med. 45 2004 553 558
30. J. Cummings, and C.S. McArdle Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug Br. J. Cancer 53 1986 835 838
31. S. Dawood, K. Broglio, F.J. Esteva, W. Yang, S.W. Kau, and R. Islam Survival among women with triple receptor-negative breast cancer and brain metastases Ann. Oncol. 20 2009 621 627
32. N.A. de Vries, J. Zhao, E. Kroon, T. Buckle, J.H. Beijnen, and O. van Tellingen P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan Clin. Cancer Res. 13 2007 6440 6449
33. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 11 2001 1156 1166
34. J.F. Deeken, and W. Loscher The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin. Cancer Res. 13 2007 1663 1674
35. A.F. Eichler, E. Chung, D.P. Kodack, J.S. Loeffler, D. Fukumura, and R.K. Jain The biology of brain metastases-translation to new therapies Nat. Rev. Clin. Oncol. 8 2011 344 356
36. A.F. Eichler, I. Kuter, P. Ryan, L. Schapira, J. Younger, and J.W. Henson Survival in patients with brain metastases from breast cancer: the importance of HER-2 status Cancer 112 2008 2359 2367
37. P.H. Elsinga, E.J.F. Franssen, N.H. Hendrikse, L. Fluks, A.M.A. Weemaes, and W.T.A. vanderGraaf Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET J. Nucl. Med. 37 1996 1571 1575
38. I.F. Faneyte, P.M. Kristel, M. Maliepaard, G.L. Scheffer, R.J. Scheper, and J.H. Schellens Expression of the breast cancer resistance protein in breast cancer Clin. Cancer Res. 8 2002 1068 1074
39. M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, and R. Grill Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group J. Clin. Oncol. 23 2005 1161 1168
40. E. Fondrinier, J.P. Muratet, E. Anglade, R. Fauvet, V. Berger, and G. Lorimier Clinical experience with 99mTc-MIBI scintimammography in patients with breast microcalcifications Breast 13 2004 316 320
41. P.M. Fracasso, K.A. Blum, M.K. Ma, B.R. Tan, L.P. Wright, and S.A. Goodner Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar Br. J. Cancer 93 2005 46 53
42. K.L. Fung, and M.M. Gottesman A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function Biochim. Biophys. Acta 1794 2009 860 871
43. T. Furukawa, K. Wakabayashi, A. Tamura, H. Nakagawa, Y. Morishima, and Y. Osawa Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations Pharm. Res. 26 2009 469 479
44. D. Fuster, N. Vinolas, C. Mallafre, J. Pavia, F. Martin, and F. Pons Tetrofosmin as predictors of tumour response Q. J. Nucl. Med. 47 2003 58 62
45. A. Gangloff, W.A. Hsueh, A.L. Kesner, D.O. Kiesewetter, B.S. Pio, and M.D. Pegram Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel J. Nucl. Med. 46 2005 1866 1871
46. S. Germano, and L. O'Driscoll Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine Curr. Cancer Drug Targets 9 2009 398 418
47. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
48. C. Grommes, G.R. Oxnard, M.G. Kris, V.A. Miller, W. Pao, and A.I. Holodny Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro Oncol. 13 2011 1364 1369
49. D.N. Hayes, S. Monti, G. Parmigiani, C.B. Gilks, K. Naoki, and A. Bhattacharjee Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts J. Clin. Oncol. 24 2006 5079 5090
50. N.H. Hendrikse, E.G.E. de Vries, E.J.F. Franssen, W. Vaalburg, and W.T.A. van der Graaf In vivo measurement of [C-11]verapamil kinetics in human tissues Eur. J. Clin. Pharmacol. 56 2001 827 829
51. T.C. Hsia, C.C. Lin, J.J. Wang, S.T. Ho, and A. Kao Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression Lung 180 2002 173 179
52. W. Hsueh, A. Kesner, A. Gangloff, M. Pegram, M. Beryt, and J. Czernin Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET J. Nucl. Med. 47 2006 1995 1999
53. Y. Huang, A.M. Ibrado, J.C. Reed, G. Bullock, S. Ray, and C. Tang Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells Leukemia 11 1997 253 257
54. H. Huo, P.G. Magro, E.C. Pietsch, B.B. Patel, and K.W. Scotto Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance Cancer Res. 70 2010 8726 8735
55. E. Jagoda, D. Kiesewetter, K. Shimoji, L. Ravasi, and W. Eckelman Comparision of the biodistribution of fluorinated and tritiated paclitaxel (PAC) in mdr1a(-)/1b(-) knockout vs wildtype mice J. Nucl. Med. 43 2002 277P
56. R.J. Kelly, R. Robey, D. Draper, C. Chen, A.M. Venkatesan, and W.D. Figg A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Proc. Am. Assoc. Can. Res. 2010 51
57. D. Kiesewetter, and W. Eckelman Radiochemical synthesis of [18F]fluoropaclitaxel ([18F]FPAC) J. Label. Cmpd. Radiopharm. 2001 S903 S905
58. Y.H. Kim, G. Ishii, K. Goto, S. Ota, K. Kubota, and Y. Murata Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer Lung Cancer 65 2009 105 111
59. D.G. Kirsch, C.J. Ledezma, C.S. Mathews, A.K. Bhan, M. Ancukiewicz, and F.H. Hochberg Survival after brain metastases from breast cancer in the trastuzumab era J. Clin. Oncol. 23 2005 2114 2116 author reply 2116-2117
60. H. Kodaira, H. Kusuhara, J. Ushiki, E. Fuse, and Y. Sugiyama Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 333 2010 788 796
61. T. Komori, I. Narabayashi, R. Matsui, K. Sueyoshi, T. Aratani, and K. Utsunomiya Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminaly report Ann. Nucl. Med. 14 2000 415 420
62. H. Koshiba, K. Hosokawa, T. Mori, A. Kubo, A. Watanabe, and H. Honjo Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo Int. J. Gynecol. Cancer 19 2009 484 488
63. K. Kurdziel, J. Kalen, J. Hirsch, J. Wilson, R. Agarwal, and D. Barrett Imaging multidrug resistance with 4-[18F]fluoropaclitaxel Nucl. Med. Biol. 34 2007 823 831
64. K.A. Kurdziel, J.D. Kalen, J.I. Hirsch, J.D. Wilson, H.D. Bear, and J. Logan Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT J. Nucl. Med. 52 2011 1339 1345
65. J.S. Lagas, R.A. van Waterschoot, R.W. Sparidans, E. Wagenaar, J.H. Beijnen, and A.H. Schinkel Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation Mol. Cancer Ther. 9 2010 319 326
66. J. Lankelma, H. Dekker, F.R. Luque, S. Luykx, K. Hoekman, and P. van der Valk Doxorubicin gradients in human breast cancer Clin. Cancer Res. 5 1999 1703 1707
67. A. Larkin, L. O'Driscoll, S. Kennedy, R. Purcell, E. Moran, and J. Crown Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study Int. J. Cancer 112 2004 286 294
68. N. Lazarova, S.S. Zoghbi, J. Hong, N. Seneca, E. Tuan, and R.L. Gladding Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function J. Med. Chem. 51 2008 6034 6043
69. M. Lehnert, K. Mross, J. Schueller, B. Thuerlimann, N. Kroeger, and H. Kupper Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer Br. J. Cancer 77 1998 1155 1163
70. C. Lemos, E. Giovannetti, P.A. Zucali, Y.G. Assaraf, G.L. Scheffer, and T. van der Straaten Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients Pharmacogenomics 12 2011 159 170
71. A. Levchenko, B.M. Mehta, J.B. Lee, J.L. Humm, F. Augensen, and O. Squire Evaluation of C-11-colchicine for PET imaging of multiple drug resistance J. Nucl. Med. 41 2000 493 501
72. C. Li, D.F. Yu, T. Inoue, D.J. Yang, W. Tansey, and C.W. Liu Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors J. Nucl. Med. 38 1997 1042 1047
73. J. Li, Z.N. Li, Y.J. Du, X.Q. Li, Q.L. Bao, and P. Chen Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival Clin. Lung Cancer 10 2009 414 421
74. J. Li, Z.N. Li, L.C. Yu, Q.L. Bao, J.R. Wu, and S.B. Shi Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy Lung Cancer 69 2010 116 122
75. X.Q. Li, J. Li, S.B. Shi, P. Chen, L.C. Yu, and Q.L. Bao Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy Int. J. Biol. Markers 24 2009 230 237
76. N.U. Lin, J.R. Bellon, and E.P. Winer CNS metastases in breast cancer J. Clin. Oncol. 22 2004 3608 3617
77. N.U. Lin, L.A. Carey, M.C. Liu, J. Younger, S.E. Come, and M. Ewend Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J. Clin. Oncol. 26 2008 1993 1999
78. N.U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, and H.J. Stemmler Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin. Cancer Res. 15 2009 1452 1459
79. B. Liu, D. Sun, W. Xia, M.C. Hung, and D. Yu Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J. Natl. Cancer Inst. 89 1997 1524 1529
80. M. Lopez, P. Vici, L. Di Lauro, G. Paoletti, T. Gionfra, and F. Conti Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer Eur. J. Cancer 31A 1995 1611 1614
81. D.A. Mankoff, L.K. Dunnwald, J.R. Gralow, G.K. Ellis, M.J. Drucker, and R.B. Livingston Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography Cancer 85 1999 2410 2423
82. L.A. Mickley, B.A. Spengler, T.A. Knutsen, J.L. Biedler, and T. Fojo Gene rearrangement: a novel mechanism for MDR-1 gene activation J. Clin. Invest. 99 1997 1947 1957
83. C. Mignogna, S. Staibano, V. Altieri, G. De Rosa, G. Pannone, and A. Santoro Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis BMC Cancer 6 2006 293
84. H.K. Mohan, and K.A. Miles Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis J. Nucl. Med. 50 2009 376 381
85. K. Morisaki, R.W. Robey, C. Ozvegy-Laczka, Y. Honjo, O. Polgar, and K. Steadman Single nucleotide polymorphisms modify the transporter activity of ABCG2 Cancer Chemother. Pharmacol. 56 2005 161 172
86. L. Moureau-Zabotto, S. Ricci, J.P. Lefranc, F. Coulet, C. Genestie, and M. Antoine Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients Br. J. Cancer 94 2006 473 480
87. K. Mross, C. Bohn, L. Edler, W. Jonat, W. Queisser, and E. Heidemann Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society Ann. Oncol. 4 1993 45 50
88. K. Mross, K. Hamm, and D.K. Hossfeld Effects of verapamil on the pharmacokinetics and metabolism of epirubicin Cancer Chemother. Pharmacol. 31 1993 369 375
89. J.R. Murren, H.J. Durivage, A.C. Buzaid, M. Reiss, S.D. Flynn, and D. Carter Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer Cancer Chemother. Pharmacol. 38 1996 65 70
90. M. Myslivecek, P. Koranda, M. Kaminek, V. Husak, M. Hartlova, and M. Duskova Technetium-99m-MIBI scintimammography by planar and SPECT imaging in the diagnosis of breast carcinoma and axillary lymph node involvement Nucl. Med. Rev. Cent. East. Eur. 7 2004 151 155
91. Y. Nishiyama, Y. Yamamoto, K. Satoh, M. Ohkawa, K. Kameyama, and E. Hayashi Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer Clin. Nucl. Med. 25 2000 364 369
92. R. O'Connor, M. O'Leary, J. Ballot, C.D. Collins, P. Kinsella, and D.E. Mager A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer Cancer Chemother. Pharmacol. 59 2007 79 87
93. S. Ota, G. Ishii, K. Goto, K. Kubota, Y.H. Kim, and M. Kojika Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Lung Cancer 64 2009 98 104
94. T. Ozulker, F. Ozulker, T. Ozpacaci, O. Bender, and H. Degirmenci The efficacy of (99m)Tc-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with X-rays mammography, ultrasonography and magnetic resonance imaging Hell. J. Nucl. Med. 13 2010 144 149
95. A. Paredes Lario, C. Blanco Garcia, M. Echenique Elizondo, and C. Lobo Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer Arch. Bronconeumol. 43 2007 479 484
96. S. Park, C. Shimizu, T. Shimoyama, M. Takeda, M. Ando, and T. Kohno Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients Breast Cancer Res. Treat. 99 2006 9 17
97. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees Molecular portraits of human breast tumours Nature 406 2000 747 752
98. C.S. Platta, D. Khuntia, M.P. Mehta, and J.H. Suh Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature Am. J. Clin. Oncol. 33 2010 398 407
99. B. Poller, D. Iusuf, R.W. Sparidans, E. Wagenaar, J.H. Beijnen, and A.H. Schinkel Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics Drug Metab. Dispos. 39 2011 729 735
100. J.W. Polli, K.L. Olson, J.P. Chism, L.S. John-Williams, R.L. Yeager, and S.M. Woodard An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5- ({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab. Dispos. 37 2009 439 442
101. L. Pusztai, P. Wagner, N. Ibrahim, E. Rivera, R. Theriault, and D. Booser Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 104 2005 682 691
102. H. Ravert, R. Klecker, J. Collins, W. Mathews, M. Pomper, and R. Wahl Radiosynthesis of [C-11]paclitaxel J. Label. Cmpd. Radiopharm. 45 2002 471 477
103. S. Ricciardi, and F. de Marinis Multimodality management of non-small cell lung cancer patients with brain metastases Curr. Opin. Oncol. 22 2010 86 93
104. F. Ries, and M. Dicato Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial Med. Oncol. Tumor Pharmacother. 8 1991 39 43
105. M. Rijavec, M. Silar, N. Triller, I. Kern, U. Cegovnik, and M. Kosnik Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients Pathol. Oncol. Res. 17 2011 691 696
106. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 26 2007 39 57
107. C. Rossi, G. Gasparini, L. Canobbio, E. Galligioni, R. Volpe, and E. Candiani Doxorubicin distribution in human breast cancer Cancer Treat. Rep. 71 1987 1221 1226
108. M. Rudas, M. Filipits, S. Taucher, T. Stranzl, G.G. Steger, and R. Jakesz Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy Breast Cancer Res. Treat. 81 2003 149 157
109. S. Rybarova, I. Hodorova, M. Hajdukova, K. Schmidtova, J. Mojzis, and K. Kajo Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters Neoplasma 53 2006 128 135
110. R. Sadeghi, S.R. Zakavi, M.N. Forghani, K. Aryana, V.R. Kakhki, and N.K. Ayati The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid Nucl. Med. Rev. Cent. East. Eur. 13 2010 1 4
111. T. Saeki, T. Nomizu, M. Toi, Y. Ito, S. Noguchi, and T. Kobayashi Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer J. Clin. Oncol. 25 2007 411 417
112. C. Saison, V. Helias, B.A. Ballif, T. Peyrard, H. Puy, and T. Miyazaki Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior Nat. Genet. 44 2012 174 177
113. F.S. Sampalis, R. Denis, D. Picard, D. Fleiszer, G. Martin, and E. Nassif International prospective evaluation of scintimammography with (99m)technetium sestamibi Am. J. Surg. 185 2003 544 549
114. A.H. Schinkel Pharmacological insights from P-glycoprotein knockout mice Int. J. Clin. Pharmacol. Ther. 36 1998 9 13
115. R. Sciuto, R. Pasqualoni, S. Bergomi, G. Petrilli, P. Vici, and F. Belli Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy J. Nucl. Med. 43 2002 745 751
116. Shaffer, B.C., Gillet, J.-P., Patel, C., Baer, M.R., Bates, S.E., Gottesman, M.M. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist. Updates, in press.
117. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med. 353 2005 123 132
118. C.M. Shih, Y.C. Shiau, J.J. Wang, S.T. Ho, and A. Kao Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression Lung 181 2003 103 111
119. S. Stallard, J.G. Morrison, W.D. George, and S.B. Kaye Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother. Pharmacol. 25 1990 286 290
120. P.S. Steeg, K.A. Camphausen, and Q.R. Smith Brain metastases as preventive and therapeutic targets Nat. Rev. Cancer 11 2011 352 363
121. D.J. Stewart Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Crit. Rev. Oncol. Hematol. 75 2010 173 234
122. S.S. Sun, J.F. Hsieh, S.C. Tsai, Y.J. Ho, J.K. Lee, and C.H. Kao Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results Cancer Lett. 153 2000 95 100
123. P. Surowiak, V. Materna, R. Matkowski, K. Szczuraszek, J. Kornafel, and A. Wojnar Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance Breast Cancer Res. 7 2005 R862 R870
124. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
125. S.C. Tang, J.S. Lagas, N.A. Lankheet, B. Poller, M.J. Hillebrand, and H. Rosing Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 130 2012 223 233
126. K.S. Taskar, V. Rudraraju, R.K. Mittapalli, R. Samala, H.R. Thorsheim, and J. Lockman Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer Pharm. Res. 29 3 2012 770 781
127. A.W. Tolcher, K.H. Cowan, D. Solomon, F. Ognibene, B. Goldspiel, and R. Chang Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer J. Clin. Oncol. 14 1996 1173 1184
128. D. Toppmeyer, A.D. Seidman, M. Pollak, C. Russell, K. Tkaczuk, and S. Verma Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel Clin. Cancer Res. 8 2002 670 678
129. N. Triller, P. Korosec, I. Kern, M. Kosnik, and A. Debeljak Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease Lung Cancer 54 2006 235 240
130. D.L. Trump, D.C. Smith, P.G. Ellis, M.P. Rogers, S.C. Schold, and E.P. Winer High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine J. Natl. Cancer Inst. 84 1992 1811 1816
131. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1981 1967 1972
132. R. Ushijima, K. Takayama, M. Izumi, T. Harada, Y. Horiuchi, and J. Uchino Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer Anticancer Res. 27 2007 4351 4358
133. J. Usuda, Y. Tsunoda, S. Ichinose, T. Ishizumi, K. Ohtani, and S. Maehara Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer Lung Cancer 67 2010 198 204
134. R. Vaclavikova, S.H. Nordgard, G.I. Alnaes, M. Hubackova, E. Kubala, and R. Kodet Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients Pharmacogenet. Genomics 18 2008 263 273
135. C.K. van Kalken, J.J. van der Hoeven, J. de Jong, G. Giaccone, G.J. Schuurhuis, and P.A. Maessen Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients Eur. J. Cancer 27 1991 739 744
136. E.W. van Tilburg, E.J.F. Franssen, J.J.M. van der Hoeven, M. van der Meij, D. Elshove, and A.A. Lammertsma Radiosynthesis of [C-11]docetaxel J. Label. Compd. Radiopharm. 47 2004 763 777
137. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher First-line Herceptin monotherapy in metastatic breast cancer Oncology 61 Suppl. 2 2001 37 42
138. E. Warner, D. Hedley, I. Andrulis, R. Myers, M. Trudeau, and D. Warr Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen Clin. Cancer Res. 4 1998 1451 1457
139. W.H. Wilson, S.E. Bates, A. Fojo, G. Bryant, Z. Zhan, and J. Regis Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy J. Clin. Oncol. 13 1995 1995 2004
140. G.C. Wishart, D. Bissett, J. Paul, D. Jodrell, A. Harnett, and T. Habeshaw Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J. Clin. Oncol. 12 1994 1771 1777
141. M.E. Witgert, and C.A. Meyers Neurocognitive and quality of life measures in patients with metastatic brain disease Neurosurg. Clin. N. Am. 22 2011 79 85 vii
142. O.M. Woodward, A. Kottgen, J. Coresh, E. Boerwinkle, W.B. Guggino, and M. Kottgen Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout Proc. Natl. Acad. Sci. U.S.A. 106 2009 10338 10342
143. L. Xiang, P. Su, S. Xia, Z. Liu, Y. Wang, and P. Gao ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma Diagn. Pathol. 6 2011 90
144. J.J. Yeh, N.Y. Hsu, W.H. Hsu, C.H. Tsai, C.C. Lin, and J.A. Liang Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer Lung 183 2005 177 183
145. J.J. Yeh, W.H. Hsu, J.J. Wang, S.T. Ho, and A. Kao Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression Respiration 70 2003 32 35
146. K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, and K. Goto Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer Clin. Cancer Res. 10 2004 1691 1697
147. M. Yuksel, T.F. Cermik, L. Doganay, C. Karlikaya, E. Cakir, and A. Salan 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis Eur. J. Nucl. Med. Mol. Imaging 29 2002 876 881
148. M. Zhou, N. Johnson, S. Gruner, G.W. Ecklund, P. Meunier, and S. Bryn Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient Am. J. Surg. 197 2009 159 163